07:51 AM EDT, 08/14/2025 (MT Newswires) -- Schrodinger (SDGR) said Thursday that it has discontinued its program for SGR-2921, which was intended to treat relapsed/refractory acute myeloid leukemia or high-risk myelodysplastic syndromes.

The company said it made the decision after SGR-2921 was considered to have contributed to the deaths of two AML patients.

Schrodinger said it "believes the path to development as a combination therapy would be difficult to pursue."

Shares of Schrodinger were down 2% in recent Thursday premarket activity.